Samsung Pharm files to amend GV1001 PSP Phase 2b/3 trial plan

Company says it submitted a protocol amendment to South Korea’s MFDS for its domestic Phase 2b/3 trial in progressive supranuclear palsy-Richardson’s syndrome. The trial targets 360 patients with a 72-week primary endpoint.